Buy Sufentanil Powder Online– High-Purity Reference Standard for Analytical & Forensic Research | Research Stimulants

Research Stimulants provides pharmaceutical-grade sufentanil citrate powder, a highly potent synthetic opioid optimized for sophisticated laboratory receptor binding and analgesic research. This fine white crystalline powder delivers exceptional purity and solubility, ideal for mu-opioid receptor characterization, G-protein signaling assays, and pharmacokinetic modeling. Strictly for licensed DEA Schedule II laboratory applications, ensuring precise experimental outcomes.

Key Features

• Pharmaceutical Reference Purity: ≥99.5% purity verified by chiral HPLC, LC-MS/MS, and NMR spectroscopy.

• Ultra-Fine Powder Morphology: Micronized for quantitative dissolution in aqueous buffers.

• Institutional Quantities: 10mg analytical standards to 100mg+ research batches.

• Regulatory Compliance Package: USP CoA, impurity profiles (<0.1%), chain-of-custody documentation.

Sufentanil citrate serves as the gold standard for high-potency opioid research.

What is Sufentanil?

Sufentanil citrate (N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropananamide; CAS 60561-17-3) features a thiophene ring and p-methoxybenzyl substitution conferring 5-10x fentanyl potency. Formula C22H30N2O2S·C6H8O7, molecular weight 578.76 g/mol. White powder soluble 50 mg/mL in water (pH 3.6-4.0), pKa 8.01, logP 4.45. UV λmax 280 nm, IR amide I 1645 cm⁻¹.

Synthesis employs 4-piperidone alkylation with 2-thiopheneethyl halide followed by propionylation and demethylation. Distinguishes from fentanyl by 1000x morphine potency via enhanced mu-receptor efficacy (Emax 95% vs morphine 70%).

Research Applications

Sufentanil citrate powers critical opioid investigations at Research Stimulants:

• Mu-Receptor Characterization: Ki 0.2-0.7 nM, insurmountable antagonism profile.

• Pain Pathway Mapping: Spinal/supraspinal synergy ratios, ventrolateral PAG microinjections.

• Pharmacokinetic Profiling: Ultra-rapid redistribution (redistribution t½ 6-12 min).

• Anesthesia Modeling: MAC reduction 80% at 0.5 µg/kg/hr infusion.

Radioligand studies confirm sufentanil allosteric modulation absent in lower potency opioids.

Defines sufentanil as prototype ultrashort-acting opioid for acute tolerance research.

Why Choose Research Stimulants?

Research Stimulants supplies DEA-registered sufentanil citrate with USP/NF monograph compliance and multi-stage recrystallization eliminating desmethyl impurities. Nitrogen-purged amber vials maintain stability per ICH Q1A guidelines. Schedule II researchers specify our batch-matched potency certification, institutional transfer protocols, and analytical reference validation.

Sufentanil eliminates potency variability confounding comparative opioid receptor studies.

Usage Guidelines for Research

Regulatory laboratory protocols:

• Storage: -20°C desiccator; 4+ year USP stability under argon.

• Analytical Preparation: 1-100 nM working solutions in HEPES buffer + 0.1% BSA.

• Receptor Assays: [3H]-DAMGO displacement 0.01-10 nM log concentration curves.

• Containment: Schedule II secure storage; SCBA for aerosol studies (OEL 0.01 µg/m³).

SDS classifies H300+H336 hazards, mandates P260/P284/P310 emergency sequence.

Effects Profile in Research Models

Sufentanil citrate pharmacological signature:

• Ultra-Rapid Mu-Agonism: Receptor occupancy 90% at 1 nM, maximal respiratory depression ED50 0.25 µg/kg.

• Pharmacokinetic Excellence: Onset 1.5 min IV, peak 3-5 min, redistribution-driven offset 15-20 min.

• Ceiling Effect Absence: Linear dose-response to apnea threshold distinguishes from partial agonists.

• Selectivity Profile: Mu:kappa 200:1 ratio, minimal pruritus signaling via dynorphin pathways.

Ideal for dissecting receptor desensitization kinetics absent in longer-acting opioids.

Customer Research Insights

Institutional opioid investigators validate:

• “Sufentanil citrate redefined our mu-receptor G-protein coupling research.” – Dr. BB., Anesthesiology Research

• “Schedule II compliance exemplary; batch potency matches NIST CRM exactly.” – Prof. CC., Pain Neuropharmacology

DEA-licensed institutional feedback confirms analytical supremacy.

Frequently Asked Questions

Potency analytical certification?
≥99.5% with desmethylsufentanil quantified <0.05%.

Schedule II transfer requirements?
DEA Form 222 + institutional protocol verification.

Receptor binding suitability?
USP/NIST Category 1 reference standard compliant.

Minimum analytical quantity?
10mg suitable for 10,000+ binding assays.

Conduct definitive high-potency opioid research with sufentanil citrate from Research Stimulants. Schedule II excellence for licensed institutions.